Literature DB >> 34173715

ROSES-S: Statement from the World Health Organization on the reporting of seroepidemiologic studies for SARS-CoV-2.

.   

Abstract

Well-designed population-based seroepidemiologic studies can be used to refine estimates of infection severity and transmission, and are therefore an important component of epidemic surveillance. However, the interpretation of the results of seroepidemiologic studies for SARS-CoV-2 has been hampered to date principally by heterogeneity in the quality of the reporting of the results of the study and a lack of standardized methods and reporting. We provide here the ROSES-S: Reporting of Seroepidemiologic studies-SARS-CoV-2. This is an updated checklist of 22 items that should be included in the reporting of all SARS-CoV-2 seroepidemiologic studies, irrespective of study design.
© 2021 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  SARS-CoV-2; emerging; infectious diseases; seroepidemiologic Studies

Year:  2021        PMID: 34173715     DOI: 10.1111/irv.12870

Source DB:  PubMed          Journal:  Influenza Other Respir Viruses        ISSN: 1750-2640            Impact factor:   4.380


  5 in total

1.  U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020-February 2022.

Authors:  Amen Ben Hamida; Myrna Charles; Christopher Murrill; Olga Henao; Kathleen Gallagher
Journal:  PLOS Glob Public Health       Date:  2022-08-05

Review 2.  Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020 to August 2021: a systematic review and meta-analysis.

Authors:  Nuzrath Jahan; Adarsha Brahma; Muthusamy Santhosh Kumar; Bhavani Shankara Bagepally; Manickam Ponnaiah; Tarun Bhatnagar; Manoj V Murhekar
Journal:  Int J Infect Dis       Date:  2021-12-28       Impact factor: 12.074

3.  Seroprevalence of SARS-CoV-2 in a Large Cohort of Italian Police Officers.

Authors:  Sergio Garbarino; Alexander Domnich; Elisabetta Costa; Irene Giberti; Stefano Mosca; Cristiano Belfiore; Fabrizio Ciprani; Giancarlo Icardi
Journal:  Int J Environ Res Public Health       Date:  2021-11-20       Impact factor: 3.390

4.  Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.

Authors:  Xuyang Tang; Abha Sharma; Maria Pasic; Patrick Brown; Karen Colwill; Hellen Gelband; H Chaim Birnboim; Nico Nagelkerke; Isaac I Bogoch; Aiyush Bansal; Leslie Newcombe; Justin Slater; Peter S Rodriguez; Guowen Huang; Sze Hang Fu; Catherine Meh; Daphne C Wu; Rupert Kaul; Marc-André Langlois; Ed Morawski; Andy Hollander; Demetre Eliopoulos; Benjamin Aloi; Teresa Lam; Kento T Abe; Bhavisha Rathod; Mahya Fazel-Zarandi; Jenny Wang; Mariam Iskilova; Adrian Pasculescu; Lauren Caldwell; Miriam Barrios-Rodiles; Zahraa Mohammed-Ali; Nandita Vas; Divya Raman Santhanam; Eo Rin Cho; Kathleen Qu; Shreya Jha; Vedika Jha; Wilson Suraweera; Varsha Malhotra; Kathy Mastali; Richard Wen; Samir Sinha; Angus Reid; Anne-Claude Gingras; Pranesh Chakraborty; Arthur S Slutsky; Prabhat Jha
Journal:  JAMA Netw Open       Date:  2022-02-01

5.  SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021.

Authors:  Hannah C Lewis; Harriet Ware; Mairead Whelan; Lorenzo Subissi; Zihan Li; Xiaomeng Ma; Anthony Nardone; Marta Valenciano; Brianna Cheng; Kim Noel; Christian Cao; Mercedes Yanes-Lane; Belinda L Herring; Ambrose Talisuna; Nsenga Ngoy; Thierno Balde; David Clifton; Maria D Van Kerkhove; David Buckeridge; Niklas Bobrovitz; Joseph Okeibunor; Rahul K Arora; Isabel Bergeri
Journal:  BMJ Glob Health       Date:  2022-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.